Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer

Zoepf, Thomas; Jakobs, Ralf; Rosenbaum, A.; Apel, D; Arnold, Jayantha; Riemann, J. F.

doi:10.1067/mge.2001.119605

Cited by 51 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were seen more recently in a small prospective trial [125]. However, another small series showed no benefit of this technique [126]. Larger prospective, controlled trials are necessary to further evaluate this modality.…”

Section: Treatmentsupporting

confidence: 79%

A Review and Update on Cholangiocarcinoma

2004

View full text Add to dashboard Cite

Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium that was first described by Durand-Fardel in 1840. Today, it continues to defy diagnosis and treatment. It is difficult to diagnose in part because of its relative rarity, and because it is clinically silent until it becomes advanced disease with obstructive symptoms. The worldwide incidence of cholangiocarcinoma has risen over the past three decades. There is marked geographic variability in the prevalence of this disease, due in large part to regional environmental risk factors. Surgical resection remains the only curative treatment, and high priorities are improving diagnostic methods, and clinical staging for resection once the disease is suspected. A recent trend towards aggressive surgical management has improved outcomes. Chemotherapy, palliative stenting, and radiation are reserved for patients who are not resectable, those with recurrence after surgery, and those who decline surgical intervention. Recent trials using combination systemic chemotherapy and neoadjuvant chemoradiation are promising, but require further study. Over the past five years, several important studies have yielded new insights into the molecular mechanisms of cholangiocarcinoma tumorigenesis. In this review we discuss epidemiology, etiologic factors, molecular pathogenesis, diagnosis, staging, and treatment of cholangiocarcinoma. Particular focus is on recent studies into the cellular and molecular pathogenesis of the disease, recent chemotherapy trials, and newer methods of staging and screening for this devastating malignancy.

show abstract

Section: Treatmentsupporting

confidence: 79%

A Review and Update on Cholangiocarcinoma

2004

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy for cholangiocarcinoma Ortner 473 However, due to a penetration depth of less than 2 mm, it cannot be recommended for the treatment of cholangiocarcinoma [31].…”

Section: Photodynamic Therapy For Cholangiocarcinoma: Photosensitizersmentioning

confidence: 99%

Photodynamic therapy for cholangiocarcinoma: overview and new developments

Ortner¹

2009

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

show abstract

“…5‐Aminolevulinic acid (5‐ALA) is a precursor of the endogenous photosensitizer Protoporphyrin IX, which is generated in the heme pathway. 5‐ALA PDT exhibits phototoxicity of only 24–48 h with a limited tumor necrosis depth of 2 mm 2 .…”

Section: Technical Aspects Of Photodynamic Therapymentioning

confidence: 99%

Photodynamic therapy of cholangiocarcinoma

Zoepf

2008

HPB

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a local photochemical tumor treatment that consists of a photosensitizing agent in combination with laser irradiation of a distinct wavelength. In some case reports and small non-randomized pilot studies, PDT has proved feasible in patients with hilar bile duct cancer. Those studies showed an astonishing long survival time of the treated patients. In the yet published two randomized controlled studies, PDT showed a significant extension of survival compared to sole bile duct stenting. A possible explanation for this improved survival is a suspected anti-tumor immunological effect induced by PDT. PDT reaches the same level of survival time as incomplete resection. The main complication is a high risk of severe bacterial cholangitis and liver abscesses requiring peri-interventional antibiotics. Skin phototoxicity, which at the beginning of PDT was the most dreaded potential complication, seems to play an ancillary role using mild light protection. As the available photosensitizers, mainly hematoporphyrin derivative (HPD), are not very effective in terms of depth of tumor necrosis, newer photosensitizers with light absorption in the near infrared spectrum and therefore deeper penetration depth are currently under investigation.

show abstract

Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer

Cited by 51 publications

References 15 publications

A Review and Update on Cholangiocarcinoma

A Review and Update on Cholangiocarcinoma

Photodynamic therapy for cholangiocarcinoma: overview and new developments

Photodynamic therapy of cholangiocarcinoma

Contact Info

Product

Resources

About